lenalidomide,ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
janssen
['revlimid', 'carvykti']
amazing data for carvykti in revlimid refractory patients at earlier (1-3) lines of therapy in rrmm. with a hazard ratio of .26, the best ever seen in this patient population. outperformed both dpd and pvd soc. carvykti was also better tolerated in this pt population. #asco2023 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.